A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study
- 1 November 2000
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 140 (5) , 722-726
- https://doi.org/10.1067/mhj.2000.110094
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Coronary Angioplasty with or without Stent Implantation for Acute Myocardial InfarctionNew England Journal of Medicine, 1999
- Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialThe Lancet, 1999
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary AngioplastyCirculation, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Changes in membrane glycoproteins of circulating platelets after coronary stent implantation.Heart, 1996
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994
- A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery DiseaseNew England Journal of Medicine, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994